Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Diego Gonzalez

Interventional Pain Medicine Albuquerque, NM Medical Doctor

NPI 1194715938 CMS profile 1165879

8300 Carmel Ave Ne Ste 500-501, Ste C, Albuquerque, NM 87122

Open in the dashboard

General payments

$34,594

386 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Diego Gonzalez of Albuquerque, NM is reported in the CMS Open Payments database as having received $34,594 across 386 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,792 75
2024 General $3,609 79
2023 General $4,544 57
2022 General $13,623 84
2021 General $3,433 44
2020 General $5,379 26
2019 General $1,214 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Diego Gonzalez
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Diego Gonzalez were reported at $2,792. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Diego Gonzalez Interventional Pain Medicine median Middle half National median
2019 $1,214 $684 $216–$2,079 $163
2020 $5,379 $382 $122–$1,109 $114
2021 $3,433 $552 $167–$1,554 $132
2022 $13,623 $605 $187–$1,924 $149
2023 $4,544 $671 $195–$1,915 $160
2024 $3,609 $684 $206–$1,837 $164
2025 $2,792 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $17,706 123 payments
  2. Nevro Corp. $6,415 104 payments
  3. Nalu Medical, Inc. $2,451 38 payments
  4. Boston Scientific Corporation $2,248 25 payments
  5. Medtronic USA, Inc. $1,884 20 payments
  6. Orthofix Medical, Inc. $1,319 7 payments
  7. Relievant Medsystems, Inc. $1,165 13 payments
  8. Globus Medical, Inc. $633 25 payments
  9. Biodelivery Sciences International, Inc. $129 8 payments
  10. Stryker Corporation $123 1 payment
  11. Other $522 22 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,512 333 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $10,230 6 payments
  3. Travel and Lodging $8,852 46 payments
  4. Consulting Fee $4,000 1 payment
Products named General payments · program years 2019–2025
  1. SYNCHROMEDII $11,604 34 payments
  2. Senza Spinal Cord Stimulation System $4,338 11 payments
  3. Nalu Neurostimulation System $2,451 38 payments
  4. INTELLIS ADAPTIVESTIM $1,848 27 payments
  5. SYNCHROMED $1,808 5 payments
  6. KYPHON EXPRESS II KYPHOPAK TRAY $1,520 35 payments
  7. FORZA $1,319 7 payments
  8. Senza $1,254 46 payments
  9. Intracept Pain $1,075 13 payments
  10. Intracept Pain $1,054 12 payments
  11. Other $10,731 204 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

18

Median for Pain Management: 951

Drug cost

$401

Median for Pain Management: $26,034

Branded share of claims

0%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone Hcl Generic 18 $401

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 40 billing codes

Paid by Medicare

$102,971

Medicare's payments for the services billed

Medicare patients

186

Average age 73

Services billed

932

105 women, 81 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 32%
Diabetes 28%
Chronic kidney disease 26%
Ischemic heart disease 24%
COPD 21%
Cancer 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

386 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in New Mexico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record